The G-CSF is used as a therapeutic drug of the febrile neutropenia in lung cancer chemotherapy, however, there were few reports that showed the effects of combination effects of G-CSF and anticancer drugs against lung cancer. In the present study, we investigated the effects of G-CSF and the combination effects of G-CSF and cisplatin on lung cancer growth. We investigated the effect of G-CSF against the LL-2 and KLN-205 cells by MTT assay and tried to detect the G-CSF receptor by RT-PCR. Next, to analyze the G-CSF effects in vivo, we transplanted the LL-2 into C57BL/6 mice, intraperitoneally administered G-CSF (30 micro/kg/day) with or without cisplatin (5 mg/kg), measured the tumor size and analyzed pathologically by HE and immunostaining. In vitro analyses, G-CSF showed no effects in LL-2 and KLN-205 cells, and RT-PCR revealed no G-CSF receptor mRNA. In vivo analyses, G-CSF alone did not significantly suppress tumor growth. However, concurrent G-CSF administration with cisplatin significantly enhanced the tumor suppressing effect of cisplatin in early stage of tumor growth. The analysis data of vWF immunostaining indicated that the neovascularization in the peripheral region of the tumors was more enhanced in G-CSF treatment mice. ELISA assay revealed that G-CSF did not influence the serum concentration of TNF-alpha and IL-12 in tumor-bearing mice. This study suggests that concurrent (combination) administration of cisplatin with G-CSF is a safe and effective method for enhancing anticancer effects and reducing chemotherapeutic agent-induced myelosuppression.
Introduction
Cytokine granulocyte colony-stimulating factor (G-CSF) is a hematopoietic growth factor which enhances the proliferation and differentiation of neutrophil precursor cells [1] . In addition, it stimulates a variety of responses in peripheral blood neutrophils including phagocytosis, superoxide production and chemotaxis [2] . G-CSF is clinically used to enhance the recovery of the number and function of neutrophils during chemotherapy-induced neutropenia in various hematogenous and nonhematogenous malignant and nonmalignant diseases [3] [4] [5] [6] [7] . However, the results of studies on G-CSF-induced tumor growth are controversial. Recently, some studies reported that G-CSF stimulates the growth of tumor cells such as colon cancer cells [8] , small lung cancer cells [9] , skin carcinoma cells and astrocytoma cells [10] [11], In contrast, Brandstetter et al. reported that G-CSF does not exhibit any effect on the proliferation of ovarian carcinoma cell lines or tumor samples despite presence of the G-CSF receptor in the tested cell lines and biopsies [12] . Moreover, G-CSF inhibits tumor growth in a B16-BL6 melanoma cell transplanted mice model [13] . However, none of these studies were conducted using concurrent administration with anticancer agents. G-CSF as an adjuvant with cytotoxic chemotherapeutic agent in cancer chemotherapy is very important to clarify its effects on tumor growth in combination with anticancer agents. Thus, to further elucidate the role of G-CSF in tumor growth, especially in combination with anticancer drugs, we used one of the most useful clinical anticancer drug cisplatins (CDDP) [14] [15] [16] [17], whose most serious side effect is bone marrow suppression [18] [19] [20] , concurrently administered with G-CSF in a transplanted lung cancer cells mouse model, and the possible mechanism responsible for the effects of G-CSF on tumor growth was studied in vitro and in vivo.
Materials and Methods

In Vitro Effects of G-CSF on Tumor Cell Proliferation
The effect of G-CSF on tumor growth in vitro was determined by 3-[4,5-dimethylthiazol-2yl]-2,5-diphenyl-tetrazolium (MTT) assay as previously described 
In Vivo Evaluation of the Effects of G-CSF on Tumor Growth
Seven week-old male C57BL/6 mice were purchased from CLEA Japan (Meguroku, Japan). LL-2 cancer cells were grown in culture, harvested and subcutaneously injected as a suspension (1.0 × 10 5 cells in 0.1 ml of serum-free medium)
into the C57BL/6 mice in the proximal dorsa midline. The mice were rando- 
Evaluation of Microvessel Density
Sections 4 micro m thick which were taken 7 days after tumor cell transplantation were de-paraffinized and incubated with anti-von Willebrand factor (vWF) rabbit antibody (DAKO Cytomation Co. Ltd., Kyoto, Japan). Immunolabelling was performed using an avidin-biotin-peroxidase technique (Vectastain ABC kit, Vector Laboratories, Burlingame, CA) followed by counterstaining with hematoxylin, and negative control slides were obtained by omitting the primary antibody. Microvessels were identified by positive staining for vWF and morphology. The individual different fields for each tissue preparation, and microvessel density were expressed as the total microvessel count in the ten fields.
Determination of Cytokines Present in Mice Serum
Serum levels of tumor necrosis factor alpha (TNF-alpha) and interleukin-12 (IL-12) were measured 21 days after tumor cells transplantation. Under ether anesthesia mice were bled 4 h after the last G-CSF injection, and the levels of TNF-alpha and IL-12 in serum samples were determined using ELISA kits (BioSource International, Inc. Camarillo, CA). Each assay was performed according to the manufacture's instructions. The sensitivity of the TNF-alpha and IL-12 ELISA kits are 3.0 pg/ml and 2.0 pg/ml, respectively. All samples and standards were run in duplicate.
Statistical Analysis
The data was expressed as the mean ± SD. P values were calculated using the Student's t-test, and p < 0.05 was considered to be statistically significant.
Results
In Vitro Effect of G-CSF on Tumor Growth
In vitro effect of G-CSF on tumor cell proliferation and the absence of G-CSF receptor mRNA in lung cancer cells. The direct effect of G-CSF on tumor cell proliferation was determined by MTT assay in two mouse cell lines. We found that LL-2 and KLN-205 cell proliferation was unchanged significantly in the presence of various concentrations of G-CSF (Figure 1 ). To ensure that the results were due to the absence of the G-CSF receptor, we investigated the G-CSF receptor mRNA in these two cell lines by RT-PCR. A 567 bp fragment of G-CSF receptor mRNA was detected only in unseparated bone marrow cells (positive control), and was not detected in these two cell lines (Figure 2 ).
In Vivo Effect of G-CSF on Tumor Growth
Next, to evaluate the effects of G-CSF on lung cancer in vivo, we studied the tumor growth in lung cancer-bearing mice model treated with G-CSF and also in 
Mechanism of the Effectiveness
To evaluate the effect of G-CSF on tumor-associated angiogenesis, immunostaining for vWF, an established endothelial cell marker, was performed. As 
Discussion
Influence on Cancer Increase of the G-CSF
Generally, the hematopoietic growth factors are widely used for neutrophil recovery during chemotherapy in solid tumors, and there were few reports whether these growth factors affect solid tumor growth and they compromise anticancer drug effects. In the present study, the effects of G-CSF on lung cancer growth were investigated. We found that the murine non-small lung cancer cell 
Mechanism of the Effectiveness
To determine the mechanisms responsible for the enhanced effect of tumor growth inhibition for concurrent administration of G-CSF with CDDP, we focused on the effect of G-CSF on tumor-associated angiogenesis as measured by vWF immunostaining, and found that treatment with G-CSF significantly enhanced tumor neovascularization. Bussolino et al. showed that G-CSF stimulates DNA synthesis followed by the endothelial cell proliferation [32] , and Natori et al. showed that bone marrow-derived endothelial progenitor cells play a role in enhanced tumor angiogenesis in an implanted colon cancer cell mouse model [33] . So, we also considered that G-CSF promotes the angiogenesis by stimulating DNA synthesis of endothelial cell and mobilizing bone marrow-derived en- In the present study, we did not detect the significant difference of TNF-alpha and IL-12 concentrations in serum taken 21 days after drug treatment among the 4 groups. As the reason of discrepancy between our data and past report, we thought the character of C57BL/6 mice, which has Th1 dominant immune system and concentration and duration of G-CSF treatment, but it is not clear for this reason of discrepancy and more research must be needed.
Limit of This Study
It is necessary for the limit of this study to examine the increase of cancer when I Cisplatin was kindly provided from Nippon Kayaku Co. Ltd.
